 Sarepta Therapeutics Inc NASDAQ: SRPT shared new functional data across multiple studies from the SRP-9001 delandistrogene moxeparvovec program for Duchenne muscular dystrophy. SRP-9001 is an investigational gene therapy under development in partnership with Roche. 